Alfred1007
2021-11-30
Bought some to keep!
Will This Beaten-Down Stock Bounce Back? 3 Things to Know<blockquote>这只遭受重创的股票会反弹吗？要知道的 3 件事</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":609960471,"tweetId":"609960471","gmtCreate":1638232074868,"gmtModify":1638232750092,"author":{"id":3570656625926041,"idStr":"3570656625926041","authorId":3570656625926041,"authorIdStr":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":69,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Bought some to keep!</p></body></html>","htmlText":"<html><head></head><body><p>Bought some to keep!</p></body></html>","text":"Bought some to keep!","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/609960471","repostId":1195739083,"repostType":4,"repost":{"id":"1195739083","kind":"news","pubTimestamp":1638184010,"share":"https://www.laohunote.com/m/news/1195739083?lang=zh_CN&edition=full","pubTime":"2021-11-29 19:06","market":"us","language":"en","title":"Will This Beaten-Down Stock Bounce Back? 3 Things to Know<blockquote>这只遭受重创的股票会反弹吗？要知道的 3 件事</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1195739083","media":"Motley Fool","summary":"All the elements are in place for a rebound.","content":"<p><b>Vertex Pharmaceuticals</b>(NASDAQ:VRTX) has given more than one investor a headache over the past year. The company's shares have suffered ever since the company announced the failure of two candidates -- one in October 2020 and one this spring -- in clinical trials. They've dropped more than 30% since the first failure. Investors worry that Vertex is struggling to expand beyond its core portfolio of cystic fibrosis (CF) treatments.</p><p><blockquote><b>顶点制药</b>（纳斯达克股票代码：VRTX）在过去的一年里让不止一位投资者头疼。自该公司宣布两名候选人（一名在 2020 年 10 月，一名在今年春天）在临床试验中失败以来，该公司的股价一直受到影响。自第一次失败以来，它们已经下跌了30%以上。投资者担心 Vertex 正在努力扩展到其囊性纤维化 (CF) 治疗核心产品组合之外。</blockquote></p><p> Considering the time Vertex shares have spent in the doldrums, you may be getting a little impatient. In fact, you may be wondering: Will this beaten-down stock ever will recover? Before answering, here are three things to know.</p><p><blockquote>考虑到顶点股票在低迷中度过的时间，你可能会有点不耐烦。事实上，您可能想知道：这只遭受重创的股票会复苏吗？在回答之前，这里有三件事需要了解。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/35efdfa23680ecdc2c35cfd21dcba413\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>1. CF may bring in billions for a long while</b></p><p><blockquote><b>1. CF可能在很长一段时间内带来数十亿的收入</b></blockquote></p><p> As I mentioned, investors' one big concern right now is about Vertex's ability to develop drugs beyond its core program. That's understandable. But it's important to put the concern into perspective. Let's consider the revenue CF treatments generate for Vertex, its market share, and how long it's likely to maintain its position in the market.</p><p><blockquote>正如我提到的，投资者目前最大的担忧是 Vertex 开发核心项目之外药物的能力。这是可以理解的。但重要的是要正确看待这个问题。让我们考虑一下 CF 治疗为 Vertex 带来的收入、其市场份额以及它可能保持其市场地位多长时间。</blockquote></p><p> CF treatments generate billions in revenue and profit for Vertex.</p><p><blockquote>CF 治疗为 Vertex 带来了数十亿美元的收入和利润。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1a492d9390c7d692f0b6b85ff9388d6f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>VRTX Net Income (Annual) data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCharts 提供的 VRTX 净利润（年度）数据</span></p></blockquote></p><p> The company is the global CF treatment market leader. In fact, the only up-and-coming treatment that may threaten its latest blockbuster Trikafta is another candidate in Vertex's pipeline. The company recently launched a phase 3 trial of that candidate. And Vertex said last year that it expects to maintain market leadership until at least the late 2030s.</p><p><blockquote>该公司是全球 CF 治疗市场的领导者。事实上，唯一可能威胁其最新大片 Trikafta 的新兴疗法是 Vertex 管道中的另一个候选疗法。该公司最近启动了该候选人的第三阶段试验。Vertex 去年表示，预计至少到 2030 年代末将保持市场领先地位。</blockquote></p><p> All of this means that Vertex isn't about to see revenue fall any time soon. So, if it takes Vertex time to reach commercialization with non-CF programs, that's OK.</p><p><blockquote>所有这些都意味着 Vertex 的收入不会很快下降。因此，如果非CF程序需要顶点时间来实现商业化，那也没关系。</blockquote></p><p> 2. Two pipeline candidates could be gamechangers</p><p><blockquote>2. 两个管道候选者可能会改变游戏规则</blockquote></p><p> Vertex is making progress in several areas beyond CF. The company is studying candidates in seven other treatment areas. Two candidates in particular have caught my eye: a treatment for blood disorders and a therapy for type 1 diabetes (T1D).</p><p><blockquote>Vertex正在CF以外的几个领域取得进展。该公司正在研究其他七个治疗领域的候选人。有两个候选药物特别引起了我的注意：一种治疗血液疾病的药物和一种治疗1型糖尿病（T1D）的药物。</blockquote></p><p> Let's start with CTX001 for blood disorders. The company has reported positive trial results in both beta thalassemia and sickle cell disease. If all continues to go well, Vertex and partner <b>CRISPR Therapeutics</b> plan to file for regulatory approval by the end of next year. The potential product could be a gamechanger because it is a designed as a one-time curative treatment. Today, treatment options for these disorders are limited.</p><p><blockquote>先从治疗血液疾病的CTX001说起。该公司报告了β地中海贫血和镰状细胞病的积极试验结果。如果一切顺利，Vertex和partner<b>CRISPR 疗法</b>计划明年底前申请监管部门审批。这种潜在的产品可能会改变游戏规则，因为它被设计为一次性治疗。如今，这些疾病的治疗选择有限。</blockquote></p><p> Farther down the road, Vertex's T1D candidate could become another key product. Treatment options for T1D pretty much boil down to administering insulin. Vertex's candidate is a stem-cell derived therapy that is meant to actually restore the body's ability to produce insulin. It did so in the first patient in a phase 1/2 trial.</p><p><blockquote>未来，Vertex 的 T1D 候选产品可能会成为另一款关键产品。T1D的治疗方案几乎可以归结为注射胰岛素。Vertex 的候选药物是一种干细胞衍生疗法，旨在实际恢复人体产生胰岛素的能力。它在1/2期试验的第一个患者中做到了这一点。</blockquote></p><p> Both of these potential products could be significant for Vertex -- and add billions to revenue.</p><p><blockquote>这两种潜在产品对 Vertex 来说都意义重大，并增加数十亿美元的收入。</blockquote></p><p> <b>3. At today's level, Vertex is a bargain</b></p><p><blockquote><b>3. 以今天的水平来看，Vertex 很划算</b></blockquote></p><p> Vertex is trading at its lowest in relation to forward earnings estimates since at least the start of last year.</p><p><blockquote>Vertex 的交易价格相对于远期盈利预期处于至少自去年年初以来的最低水平。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9a33e676553135e9cc6a3fe0e0123498\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>VRTX PE Ratio (Forward) data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCharts 提供的 VRTX 市盈率（远期）数据</span></p></blockquote></p><p> This looks like a bargain considering the strength of Vertex's CF portfolio and the company's potential products on the horizon. In the worst scenario, Vertex may continue to bring in billions of dollars in revenue from the CF program -- but take a while to bring a non-CF product to market. In the best scenario, Vertex could generate revenue from a non-CF blockbuster -- CXT001 -- as early as in 2023. This is considering a late 2022 regulatory filing and six to 10 months review time. And that's on top of CF product revenue growth.</p><p><blockquote>考虑到 Vertex 的 CF 产品组合的实力以及该公司即将推出的潜在产品，这看起来很划算。在最坏的情况下，Vertex 可能会继续从 CF 项目中带来数十亿美元的收入，但需要一段时间才能将非 CF 产品推向市场。在最好的情况下，Vertex 最早可以在 2023 年从非 CF 大片 CXT001 中产生收入。这是在考虑2022年底的监管备案和6到10个月的审查时间。这还不包括 CF 产品收入的增长。</blockquote></p><p> In either case, Vertex today is looking inexpensive.</p><p><blockquote>无论哪种情况，Vertex 今天看起来都很便宜。</blockquote></p><p> <b>So, will Vertex bounce back?</b></p><p><blockquote><b>那么，顶点会反弹吗？</b></blockquote></p><p> Of course, no one can say for sure if Vertex shares will climb. But the company has the elements necessary for a rebound -- and eventual gains. I'm talking about blockbuster revenue and market leadership well into the future, and promising candidates in the pipeline. These factors are key to driving a biotech stock higher over time.</p><p><blockquote>当然，没有人能确定顶点股价是否会上涨。但该公司拥有反弹和最终收益所需的要素。我说的是未来的巨额收入和市场领导地位，以及正在酝酿中的有前途的候选人。这些因素是推动生物技术股票随着时间的推移而走高的关键。</blockquote></p><p> I'm not expecting Vertex's rebound to happen overnight. The clinical trial failures seriously shook investor confidence. But if Vertex announces more and more positive news from its blood disorders and T1D programs, it has a strong chance of winning that confidence back.</p><p><blockquote>我预计 Vertex 的反弹不会在一夜之间发生。临床试验失败严重动摇了投资者的信心。但如果 Vertex 宣布其血液疾病和 T1D 项目越来越多的积极消息，它就有很大的机会赢回这种信心。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will This Beaten-Down Stock Bounce Back? 3 Things to Know<blockquote>这只遭受重创的股票会反弹吗？要知道的 3 件事</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill This Beaten-Down Stock Bounce Back? 3 Things to Know<blockquote>这只遭受重创的股票会反弹吗？要知道的 3 件事</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-11-29 19:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Vertex Pharmaceuticals</b>(NASDAQ:VRTX) has given more than one investor a headache over the past year. The company's shares have suffered ever since the company announced the failure of two candidates -- one in October 2020 and one this spring -- in clinical trials. They've dropped more than 30% since the first failure. Investors worry that Vertex is struggling to expand beyond its core portfolio of cystic fibrosis (CF) treatments.</p><p><blockquote><b>顶点制药</b>（纳斯达克股票代码：VRTX）在过去的一年里让不止一位投资者头疼。自该公司宣布两名候选人（一名在 2020 年 10 月，一名在今年春天）在临床试验中失败以来，该公司的股价一直受到影响。自第一次失败以来，它们已经下跌了30%以上。投资者担心 Vertex 正在努力扩展到其囊性纤维化 (CF) 治疗核心产品组合之外。</blockquote></p><p> Considering the time Vertex shares have spent in the doldrums, you may be getting a little impatient. In fact, you may be wondering: Will this beaten-down stock ever will recover? Before answering, here are three things to know.</p><p><blockquote>考虑到顶点股票在低迷中度过的时间，你可能会有点不耐烦。事实上，您可能想知道：这只遭受重创的股票会复苏吗？在回答之前，这里有三件事需要了解。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/35efdfa23680ecdc2c35cfd21dcba413\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>1. CF may bring in billions for a long while</b></p><p><blockquote><b>1. CF可能在很长一段时间内带来数十亿的收入</b></blockquote></p><p> As I mentioned, investors' one big concern right now is about Vertex's ability to develop drugs beyond its core program. That's understandable. But it's important to put the concern into perspective. Let's consider the revenue CF treatments generate for Vertex, its market share, and how long it's likely to maintain its position in the market.</p><p><blockquote>正如我提到的，投资者目前最大的担忧是 Vertex 开发核心项目之外药物的能力。这是可以理解的。但重要的是要正确看待这个问题。让我们考虑一下 CF 治疗为 Vertex 带来的收入、其市场份额以及它可能保持其市场地位多长时间。</blockquote></p><p> CF treatments generate billions in revenue and profit for Vertex.</p><p><blockquote>CF 治疗为 Vertex 带来了数十亿美元的收入和利润。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1a492d9390c7d692f0b6b85ff9388d6f\" tg-width=\"720\" tg-height=\"449\" width=\"100%\" height=\"auto\"><span>VRTX Net Income (Annual) data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCharts 提供的 VRTX 净利润（年度）数据</span></p></blockquote></p><p> The company is the global CF treatment market leader. In fact, the only up-and-coming treatment that may threaten its latest blockbuster Trikafta is another candidate in Vertex's pipeline. The company recently launched a phase 3 trial of that candidate. And Vertex said last year that it expects to maintain market leadership until at least the late 2030s.</p><p><blockquote>该公司是全球 CF 治疗市场的领导者。事实上，唯一可能威胁其最新大片 Trikafta 的新兴疗法是 Vertex 管道中的另一个候选疗法。该公司最近启动了该候选人的第三阶段试验。Vertex 去年表示，预计至少到 2030 年代末将保持市场领先地位。</blockquote></p><p> All of this means that Vertex isn't about to see revenue fall any time soon. So, if it takes Vertex time to reach commercialization with non-CF programs, that's OK.</p><p><blockquote>所有这些都意味着 Vertex 的收入不会很快下降。因此，如果非CF程序需要顶点时间来实现商业化，那也没关系。</blockquote></p><p> 2. Two pipeline candidates could be gamechangers</p><p><blockquote>2. 两个管道候选者可能会改变游戏规则</blockquote></p><p> Vertex is making progress in several areas beyond CF. The company is studying candidates in seven other treatment areas. Two candidates in particular have caught my eye: a treatment for blood disorders and a therapy for type 1 diabetes (T1D).</p><p><blockquote>Vertex正在CF以外的几个领域取得进展。该公司正在研究其他七个治疗领域的候选人。有两个候选药物特别引起了我的注意：一种治疗血液疾病的药物和一种治疗1型糖尿病（T1D）的药物。</blockquote></p><p> Let's start with CTX001 for blood disorders. The company has reported positive trial results in both beta thalassemia and sickle cell disease. If all continues to go well, Vertex and partner <b>CRISPR Therapeutics</b> plan to file for regulatory approval by the end of next year. The potential product could be a gamechanger because it is a designed as a one-time curative treatment. Today, treatment options for these disorders are limited.</p><p><blockquote>先从治疗血液疾病的CTX001说起。该公司报告了β地中海贫血和镰状细胞病的积极试验结果。如果一切顺利，Vertex和partner<b>CRISPR 疗法</b>计划明年底前申请监管部门审批。这种潜在的产品可能会改变游戏规则，因为它被设计为一次性治疗。如今，这些疾病的治疗选择有限。</blockquote></p><p> Farther down the road, Vertex's T1D candidate could become another key product. Treatment options for T1D pretty much boil down to administering insulin. Vertex's candidate is a stem-cell derived therapy that is meant to actually restore the body's ability to produce insulin. It did so in the first patient in a phase 1/2 trial.</p><p><blockquote>未来，Vertex 的 T1D 候选产品可能会成为另一款关键产品。T1D的治疗方案几乎可以归结为注射胰岛素。Vertex 的候选药物是一种干细胞衍生疗法，旨在实际恢复人体产生胰岛素的能力。它在1/2期试验的第一个患者中做到了这一点。</blockquote></p><p> Both of these potential products could be significant for Vertex -- and add billions to revenue.</p><p><blockquote>这两种潜在产品对 Vertex 来说都意义重大，并增加数十亿美元的收入。</blockquote></p><p> <b>3. At today's level, Vertex is a bargain</b></p><p><blockquote><b>3. 以今天的水平来看，Vertex 很划算</b></blockquote></p><p> Vertex is trading at its lowest in relation to forward earnings estimates since at least the start of last year.</p><p><blockquote>Vertex 的交易价格相对于远期盈利预期处于至少自去年年初以来的最低水平。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9a33e676553135e9cc6a3fe0e0123498\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>VRTX PE Ratio (Forward) data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>YCharts 提供的 VRTX 市盈率（远期）数据</span></p></blockquote></p><p> This looks like a bargain considering the strength of Vertex's CF portfolio and the company's potential products on the horizon. In the worst scenario, Vertex may continue to bring in billions of dollars in revenue from the CF program -- but take a while to bring a non-CF product to market. In the best scenario, Vertex could generate revenue from a non-CF blockbuster -- CXT001 -- as early as in 2023. This is considering a late 2022 regulatory filing and six to 10 months review time. And that's on top of CF product revenue growth.</p><p><blockquote>考虑到 Vertex 的 CF 产品组合的实力以及该公司即将推出的潜在产品，这看起来很划算。在最坏的情况下，Vertex 可能会继续从 CF 项目中带来数十亿美元的收入，但需要一段时间才能将非 CF 产品推向市场。在最好的情况下，Vertex 最早可以在 2023 年从非 CF 大片 CXT001 中产生收入。这是在考虑2022年底的监管备案和6到10个月的审查时间。这还不包括 CF 产品收入的增长。</blockquote></p><p> In either case, Vertex today is looking inexpensive.</p><p><blockquote>无论哪种情况，Vertex 今天看起来都很便宜。</blockquote></p><p> <b>So, will Vertex bounce back?</b></p><p><blockquote><b>那么，顶点会反弹吗？</b></blockquote></p><p> Of course, no one can say for sure if Vertex shares will climb. But the company has the elements necessary for a rebound -- and eventual gains. I'm talking about blockbuster revenue and market leadership well into the future, and promising candidates in the pipeline. These factors are key to driving a biotech stock higher over time.</p><p><blockquote>当然，没有人能确定顶点股价是否会上涨。但该公司拥有反弹和最终收益所需的要素。我说的是未来的巨额收入和市场领导地位，以及正在酝酿中的有前途的候选人。这些因素是推动生物技术股票随着时间的推移而走高的关键。</blockquote></p><p> I'm not expecting Vertex's rebound to happen overnight. The clinical trial failures seriously shook investor confidence. But if Vertex announces more and more positive news from its blood disorders and T1D programs, it has a strong chance of winning that confidence back.</p><p><blockquote>我预计 Vertex 的反弹不会在一夜之间发生。临床试验失败严重动摇了投资者的信心。但如果 Vertex 宣布其血液疾病和 T1D 项目越来越多的积极消息，它就有很大的机会赢回这种信心。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/11/29/will-this-beaten-down-stock-bounce-back/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/11/29/will-this-beaten-down-stock-bounce-back/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195739083","content_text":"Vertex Pharmaceuticals(NASDAQ:VRTX) has given more than one investor a headache over the past year. The company's shares have suffered ever since the company announced the failure of two candidates -- one in October 2020 and one this spring -- in clinical trials. They've dropped more than 30% since the first failure. Investors worry that Vertex is struggling to expand beyond its core portfolio of cystic fibrosis (CF) treatments.\nConsidering the time Vertex shares have spent in the doldrums, you may be getting a little impatient. In fact, you may be wondering: Will this beaten-down stock ever will recover? Before answering, here are three things to know.\nIMAGE SOURCE: GETTY IMAGES.\n1. CF may bring in billions for a long while\nAs I mentioned, investors' one big concern right now is about Vertex's ability to develop drugs beyond its core program. That's understandable. But it's important to put the concern into perspective. Let's consider the revenue CF treatments generate for Vertex, its market share, and how long it's likely to maintain its position in the market.\nCF treatments generate billions in revenue and profit for Vertex.\nVRTX Net Income (Annual) data by YCharts\nThe company is the global CF treatment market leader. In fact, the only up-and-coming treatment that may threaten its latest blockbuster Trikafta is another candidate in Vertex's pipeline. The company recently launched a phase 3 trial of that candidate. And Vertex said last year that it expects to maintain market leadership until at least the late 2030s.\nAll of this means that Vertex isn't about to see revenue fall any time soon. So, if it takes Vertex time to reach commercialization with non-CF programs, that's OK.\n2. Two pipeline candidates could be gamechangers\nVertex is making progress in several areas beyond CF. The company is studying candidates in seven other treatment areas. Two candidates in particular have caught my eye: a treatment for blood disorders and a therapy for type 1 diabetes (T1D).\nLet's start with CTX001 for blood disorders. The company has reported positive trial results in both beta thalassemia and sickle cell disease. If all continues to go well, Vertex and partner CRISPR Therapeutics plan to file for regulatory approval by the end of next year. The potential product could be a gamechanger because it is a designed as a one-time curative treatment. Today, treatment options for these disorders are limited.\nFarther down the road, Vertex's T1D candidate could become another key product. Treatment options for T1D pretty much boil down to administering insulin. Vertex's candidate is a stem-cell derived therapy that is meant to actually restore the body's ability to produce insulin. It did so in the first patient in a phase 1/2 trial.\nBoth of these potential products could be significant for Vertex -- and add billions to revenue.\n3. At today's level, Vertex is a bargain\nVertex is trading at its lowest in relation to forward earnings estimates since at least the start of last year.\nVRTX PE Ratio (Forward) data by YCharts\nThis looks like a bargain considering the strength of Vertex's CF portfolio and the company's potential products on the horizon. In the worst scenario, Vertex may continue to bring in billions of dollars in revenue from the CF program -- but take a while to bring a non-CF product to market. In the best scenario, Vertex could generate revenue from a non-CF blockbuster -- CXT001 -- as early as in 2023. This is considering a late 2022 regulatory filing and six to 10 months review time. And that's on top of CF product revenue growth.\nIn either case, Vertex today is looking inexpensive.\nSo, will Vertex bounce back?\nOf course, no one can say for sure if Vertex shares will climb. But the company has the elements necessary for a rebound -- and eventual gains. I'm talking about blockbuster revenue and market leadership well into the future, and promising candidates in the pipeline. These factors are key to driving a biotech stock higher over time.\nI'm not expecting Vertex's rebound to happen overnight. The clinical trial failures seriously shook investor confidence. But if Vertex announces more and more positive news from its blood disorders and T1D programs, it has a strong chance of winning that confidence back.","news_type":1,"symbols_score_info":{"VRTX":0.9}},"isVote":1,"tweetType":1,"viewCount":1208,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":17,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/609960471"}
精彩评论